| abstract |
A new combination therapy is described for cardiovascular diseases, in particular essential hypertension, pulmonary hypertension and / or congestive heart failure, administering a synergistic combination of at least one neutral endopeptidase inhibitor, at least one inhibitor of the endogenous endothelin producing system and , at least one antagonist the AT1 receptor. Kit comprising said therapy. |